Healthcare / BiotechnologyNasdaqGS
$4.21
-0.12 (-2.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-49.3M · quality 52.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$152M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-66.3%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-35.2M · FCF $-29.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Net Income | $-35.2M | $-35.2M | $-51.3M | $-64.7M | $-41.0M | $-21.5M |
| EBITDA | $-38.1M | $-38.1M | $-54.6M | $-69.6M | $-42.3M | — |
| EPS | — | — | -1.72 | -2.74 | -2.79 | -10.64 |
| Balance Sheet | ||||||
| Debt/Equity | — | — | — | — | 0.00 | — |
| Current Ratio | 15.73 | 15.73 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-29.8M | $-29.8M | $-49.3M | $-53.3M | $-33.5M | — |
| Returns | ||||||
| ROE | -66.3% | -66.3% | -62.7% | -51.9% | -42.9% | 45.4% |
| Valuation | ||||||
| P/B | 2.18 | 2.18 | 0.52 | 3.62 | 1.63 | — |
| Growth & Yield | ||||||
| EPS Growth | — | — | 37.2% | 1.8% | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+297.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.72 → n/d
Residual
+297.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.